Global Omalizumab Biosimilars Market Size Likely to Grow at a CAGR of 14.15% By 2035

The global Omalizumab Biosimilars market size is projected to touch almost USD 1.65 billion by 2025 and nearly USD 1.88 billion by 2026 with an expected reach of about USD 6.20 billion by 2035, growing at a CAGR of 14.15% over the 2026-2035 forecast period.

Omalizumab Biosimilars Market  Revenue and Trends

The market for Omalizumab Biosimilars is constantly growing owing to the wide applications and patient preferences across age groups, attributing to the high safety and efficacy for chronic allergic diseases like asthma and chronic urticaria. Increase in number of allergic and immune diseases coupled with growing awareness regarding biologic therapies has driven the growth. Furthermore, easy availability of healthcare services and expansion of health infrastructure alongside the growing acceptance of cheaper treatment alternatives over expensive branded biologic alternatives, especially in emerging economies, has boosted its growth. In addition, enhancement of biopharmaceutical manufacturing, increased investments from the key market players, and government initiatives have also been instrumental in expanding production and accessibility, ensuring a steady long-term growth.

What are the main growth drivers of Omalizumab Biosimilars Market?

This market for Omalizumab Biosimilars is experiencing a robust growth owing to increasing prevalence of chronic allergic diseases including asthma, chronic spontaneous urticarial etc and also rising demand for low cost biological treatments which have efficacy and safety comparable to reference drugs. Growing awareness among consumers about novel biological therapies along with increasing diagnostic rates and the necessity of lifelong disease management is also fueling the use of biosimilars for different segments of patients. Moreover increase in healthcare access along with escalating health awareness and intense desire among healthcare givers for cost control will prove instrumental in escalating market growth, especially for the emerging economies.

In addition growing progress in biopharmaceutical manufacturing technologies including advancements in formulation methods and higher production efficiency is expected to result in massive production and wider availability of more affordable biosimilars. Robust R&D pipelines along with increased investment from drug manufacturers coupled with strategic alliances between them will fuel market growth significantly. Favorable regulatory policies, a shift toward more sustainable health care solutions and growing concerns over safe and cost effective long-term management of allergic diseases will contribute largely toward market expansion of the Omalizumab Biosimilars over the projected years.

Segment Insight

• By Product Type: Monoclonal Antibody Biosimilars account for the largest share of the Omalizumab Biosimilars Market owing to their high specificity, proven clinical efficacy and the use in treating allergic diseases. Recombinant Anti-IgE Biosimilars are gaining traction for its targeted action in inhibiting IgE, neutralizing all forms of IgE and in treating allergic disorders it acts with more efficiency against allergic diseases as they are long-term conditions. Long-acting biosimil formulations are expected to register the highest growth rate over the forecast period owing to the extended dosage intervals which leads to enhanced patient compliance, improved adherence, and prolonged therapeutic effects. Other product types are expected to show a steady growth with expanding pipeline and advancements in technology.

• By Indication: Allergic Asthma dominates the market as the disorder is highly prevalent across the globe, while omalizumab biosimilars are effective in treating moderate-to-severe allergic asthma. Chronic Spontaneous Urticaria represents a significant share of the market for this indication due to the increase in diagnosis rates, long term control over symptoms and is expected to grow significantly over the forecast period. Allergic Rhinitis and Nasal Polyps are a niche in the market that is being catered to as they hold potential for omalizumab biosimilars for their efficacy and usage; and are expected to gain considerable attention. Atopic Dermatitis is also a major indication that is expected to see a steady growth rate over the forecast period as biologic therapy finds its way more often for atopic dermatitis and hence, for omalizumab biosimilars. Other indications such as anaphylaxis and asthma are expected to show a steady growth with increasing research.

• By Route of Administration: Subcutaneous Injection accounts for the largest market share in this segment owing to its established efficacy, easy administration, and common usage in biologic therapies. Intravenous injection has a much smaller share in the Omalizumab Biosimilars market for omalizumab, it does represent a share of its own. However with the advancement in drug delivery system, the innovation and usage of the market are increasing in each segment by some factor, by considering all the parameters it can be easily concluded that subcutaneous injection accounts for the majority share.

Region Analysis

North America has the highest share in the Omalizumab Biosimilars Market due to factors such as advanced healthcare infrastructure, high adoption of biologics and well-established market presence of major key players in the market. Europe accounted for a significant share in the market due to regulatory framework supporting the biosimilars and increasing number of approvals. The Asia-Pacific region is expected to register a substantial growth due to the rising prevalence of allergic diseases, expanding healthcare infrastructure, and awareness in countries like China and India. While Latin America and the Middle East & Africa regions are expected to grow at a steady pace supported by increased accessibility to healthcare and growing demand for affordable biologics.

Report Scope

Recent Developments

• Amgen Inc. had launched the development of Omalizumab Biosimilars Market with strategic developments in February 2024 to improve the biosimilars pipeline through strong R&D activities and enhanced manufacturing capabilities. Amgen Inc. invested in advanced biologic development, improving manufacturing efficiency, and creating strategic partnerships in order to gain a larger reach in the market and to bring affordable biologic treatments to patients who suffer from allergies such as allergic asthma and chronic spontaneous urticaria.

List of the prominent players in the Omalizumab Biosimilars Market:

• Novartis AG

• Genentech (Roche Group)

• F. Hoffmann-La Roche Ltd

• Teva Pharmaceutical Industries Ltd

• Sandoz Group AG

• Amgen Inc.

• Celltrion Inc.

• Samsung Bioepis Co. Ltd.

• Biocon Biologics Ltd.

• Dr. Reddy’s Laboratories Ltd.

• Biogen Inc.

• Pfizer Inc.

• Merck & Co. Inc.

• AbbVie Inc.

• Amneal Pharmaceuticals LLC

• Fresenius Kabi AG

• STADA Arzneimittel AG

• Alvotech

• Lupin Limited

• Intas Pharmaceuticals Ltd.

• Others

The Omalizumab Biosimilars Market is segmented as follows:

By Product Type

• Monoclonal Antibody Biosimilars

• Recombinant Anti-IgE Biosimilars

• Long-acting Biosimilar Formulations

By Indication

• Allergic Asthma

• Chronic Spontaneous Urticaria (CSU)

• Allergic Rhinitis

• Nasal Polyps

• Atopic Dermatitis

• Other

By Route of Administration

• Subcutaneous Injection

• Intravenous

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America